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Because ketamine and magnesium block NMDA receptor activation by distinct mechanisms of action, we hypothesized that in a model 
of inflammatory pain in rats the combination of ketamine and magnesium might be more effective than ketamine alone. 
Antinociceptive activity was assessed by the formalin test in male Wistar rats (200–250 g). Animals were injected with 100 μL of 2.5% 
formalin to the plantar surface of the right hind paw. Data were recorded as the total time spent in pain‑related behavior after the 
injection of formalin or vehicle (0.9% NaCl). 
Ketamine and magnesium sulfate given separately reduced nocifensive behavior in the second phase of the formalin test in rats. 
When ketamine was applied after magnesium sulfate, the log dose‑response curves for the effects of ketamine and the magnesium 
sulfate‑ketamine combination revealed antagonistic interaction, and about 1.6 (CL 1.2–2.4) fold increment in ketamine dosage. A low 
dose of magnesium sulfate (5 mg/kg, subcutaneously) administered after ketamine increased the antinociceptive effect of ketamine 
by a factor of only 1.2 (CL 0.95–1.38), indicating an additive interaction. There was a 1.8‑fold reduction in dosage of ketamine when 
ketamine was administered before rather than after the magnesium sulfate.
The present study revealed that both ketamine and magnesium reduced pain‑related behavior in the second phase of the formalin test 
in rats. Ketamine, when administered before or after the magnesium, provided additive or antagonistic antinociceptive interactions, 
respectively. Whether there will be an additive or antagonistic antinociceptive interaction between ketamine and magnesium depends 
on the order of drug administration. 
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INTRODUCTION
The formalin model test is widely used for evaluating 
the effects of antinociceptive drugs in laboratory 
animals. Injection of formalin into the hind paw induces 
a biphasic pain response; the first phase is result 
from direct activation of primary afferent sensory 
neurons, whereas the second phase has been proposed 
to reflect the combined effects of afferent input and 
central sensitization in the dorsal horn (Mcnamara et 
al. 2007, Tjølsen et al. 1992, Pitcher and Henry 2002). 
Central sensitization is involved in the establishment 
of chronic neuropathic or inflammatory pain. The 
N‑methyl‑D‑aspartate (NMDA) receptor plays a key role 
in mechanisms relating to central sensitization in the 
spinal cord (Latremoliere and Woolf 2009). Magnesium is 
the fourth most abundant essential ion in the human body 
and has a fundamental role in many cellular functions, 
such as storage, metabolism and energy utilization, 
and there is therefore increasing interest in its role in 
clinical medicine (Herroeder et al. 2011). Magnesium 
ions serve as cofactors in about 300 known enzymatic 
reactions in the body and in several important processes 
such as hormone receptor binding, gating of calcium 
channels, transmembrane ion flux, regulation of the 
adenylyl cyclase system, neuronal activity, vasomotor 
tone, cardiac excitability and neurotransmitter release 
(Schulz‑Stübner et al. 2001). As magnesium blocks the 
NMDA receptor and its associated ion channels, it can 
prevent the central sensitization caused by peripheral 
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nociceptive stimulation (Schulz‑Stübner et al. 2001, Liu 
et al. 2001, Cavalcante et al. 2013). However, there are 
controversial results in studies in which the effects of 
magnesium in models of somatic inflammatory pain 
were investigated (Begon et al. 2002, Takano et al. 2000).
Ketamine, a dissociative anesthetic, is the most 
potent NMDA‑receptor‑channel blocker available for 
clinical use. Ketamine binds to the phencyclidine site 
when the channels are in the open activated state (Øye 
1998, Quibell et al. 2011). It can also bind to a second 
membrane‑associated site, that, decreases the frequency 
of channel opening (Orser et al. 1997b). Blocking NMDA 
receptors with ketamine reduces central sensitization 
and wind‑up, resulting in pain reduction. Several lines of 
evidence indicate that at subanesthetic doses ketamine 
is effective against neuropathic and inflammatory pain. 
However, its use as the only antinociceptive drug is 
limited because of the high incidence of adverse effects 
(Shimoyama et al. 1999, Hirota and Lambert 2011, Niesters 
et al. 2014).
It has been reported that magnesium can either 
increase or decrease the antinociceptive, anesthetic 
or other actions of ketamine (Irifune et al. 1992, 
DeRossi et al. 2012, Jahangiri et al. 2013, Macdonald 
et al. 1991, Stessel et al. 2013). However, a statistically 
significant interaction (synergistic) between ketamine 
and magnesium was described in only three studies 
(Liu et al. 2001, Vučković et al. 2014, Savic Vujovic 
et al. 2015). In addition, Orser and others (1997a) 
demonstrated that low blood levels of magnesium or 
a magnesium‑deficient diet increased the sensitivity to 
ketamine.
Because ketamine and magnesium block NMDA 
receptor activation by distinct mechanisms of 
action, we hypothesized that in inflammatory pain, 
a combination of ketamine and magnesium might be 
more effective than ketamine alone. Therefore, the 
objective of the present study was to determine the 
type of interaction between systemic magnesium 
sulfate and ketamine in the second phase of the rat 
formalin test, and to determine the importance of the 
order of drug administration.
METHODS
Subjects
The study was performed using 96 male Wistar rats 
(Military Farm, Belgrade, Serbia) weighing 200–250 g. 
The experimental animals were handled as prescribed by 
the Ethics Committee for Animal Research and Welfare of 
the Faculty of Medicine, University of Belgrade (Permit 
N° 3416/2). All experiments were approved by the Ethical 
Council for the Protection of Experimental Animals of the 
Ministry of Agriculture, Forestry and Water Management 
of the Republic of Serbia, which operates in accordance 
with the Animal Welfare Law of the Republic of Serbia 
and the International Association for the Study of Pain 
(IASP) Guidelines for the Use of Animals in Research. 
The animals were housed in groups of three in Plexiglas 
cages (42.5×27×19 cm) under standard conditions of 
temperature (22±1°C), relative humidity (60%) and a 12 h 
light/dark cycle, with lights on at 8:00 a.m. Food and water 
were freely available, except during the experimental 
procedures. The animals were fed standard rat pellets 
obtained from the Veterinary Institute Subotica, 
Serbia. The experiments were conducted by the same 
experimenter on consecutive days, always at the same 
time of the day, between 8:00 a.m. and 2:00 p.m., to avoid 
diurnal variation in the behavioral tests. The animals 
were unrestrained during testing. Each animal was used 
only once and was killed at the end of the experiments 
by an intraperitoneal (ip) injection of sodium thiopental 
(200 mg/kg).
Administration of drugs
Ketamine at doses of 2, 2.5 and 5 mg/kg (InresaArzneimittel 
GmbH, Freiburg, Germany) and magnesium sulfate at 
doses of 5, 15 and 30 mg/kg (Zorka, Šabac, Serbia) were 
dissolved in 0.9% NaCl and injected subcutaneously (sc) 
and intraperitoneally (ip), respectively, in a final volume of 
2 ml/kg. Magnesium sulfate was administered either 5 min 
before or after ketamine injection. Formalin (2.5%, 100 μL) was 
injected into the right hind paw surface (intraplantar‑ipl) of 
rats 5 min after ketamine/magnesium sulfate. To test whether 
the 0.9% NaCl injection had any effect on the antinociception, 
the same volume of 0.9% NaCl was administered to a control 
group of rats.
Formalin test
Animals were injected with 100 μL of 2.5% formalin 
into the plantar surface of the right hind paw using 
a microliter syringe and a 29‑gauge needle. After formalin 
injection, the animals were individually placed in 
transparent observation chambers. Data were recorded as 
the total time spent in pain‑related behavior (the injected 
paw was elevated and not in contact with any surface; 
animal licked or bit the injected paw) after the injection 
of formalin or vehicle (Makau et al. 2014). The nociceptive 
time was calculated duringthe first phase (0–10 min) and 
second phase (10–45 min) after formalin injection. The 
recordings were performed in 9 blocks of 5 min (Makau 
et al. 2014).
5_882_Vujovic_v5.indd   138 23/06/17   19:09
Magnesium and ketamine in the formalin test 139Acta Neurobiol Exp 2017, 77: 137–146
Data analysis
The results are presented as the means ±SEM for 6–8 
animals per group. The time‑course of the antinociceptive 
responses of individual drugs and their combinations were 
constructed by plotting the mean time that the animal 
spent in pain‑related behavior as a function of time. The 
areas delineated by the pain‑related behavior and the 
time curves (AUC) were calculated using the trapezoidal 
rule. AUC was calculated for the second phase of the assay 
and the percentage of antinociception was calculated 
according to the following equation (Jiménez‑Andrade et 
al. 2003):
Percent of antinociception (AA%)=[(AUCvehicle‑AUCpost 
compound)/AUCvehicle]×100.
Analysis of the interaction between drugs with 
a high and a low antinociceptive efficacy
The interaction between ketamine (the drug that 
possessed a high antinociceptive efficacy and exhibited 
a dose‑dependent effect in the formalin test) with 
magnesium sulfate (the drug with a low antinociceptive 
efficacy in the formalin test) was evaluated by 
the administration of a fixed, subeffective dose of 
magnesium sulfate with increasing doses of ketamine 
(Gaitan and Herrero 2002). The antinociceptive effects 
of ketamine were examined and the ED50 value obtained 
from the corresponding log dose‑response curve. 
The effects of magnesium sulfate were examined for 
a specific dose range (based on the literature data). 
The lowest subeffective dose tested was chosen for 
the combination in experiments. In the next step, the 
effects of ketamine‑magnesium sulfate combinations 
were examined. We combined fixed‑dose fractions 
of the ED50 of ketamine (1 ED50, 5/4 ED50, 2 ED50) with 
a fixed dose of magnesium sulfate (5 mg/kg). To 
determine the type of interaction, the regression log 
dose‑response curves for ketamine alone were compared 
to the log dose‑response curves for ketamine in the 
presence of magnesium sulfate. The same procedure 
was performed for the determination of the type of 
interaction between ketamine and magnesium sulfate 
when magnesium sulfate was administered either before 
or after ketamine. If there is a significant leftward 
shift of the log dose‑response curves, the interaction 
between the components is supra‑additive (synergistic). 
If the curves overlap, there is an additive interaction 
(Tallarida 2000). If there is a significant rightward shift 
Fig. 1.The antinociceptive effect of magnesium sulfate in the formalin test in rats. Each point represents the mean ±SEM of the antinociceptive latency 
time in seconds (s) obtained in 6–8 rats. At each time interval the differences between the corresponding means were verified using one‑way analysis of 
variance (ANOVA; F‑value, p‑value), followed by Tukey’s HSD post hoc test where statistical significance was determined by comparing with the control 
(0.9% NaCl) (*P<0.05). 
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of the log dose‑response curves, the interaction between 
compounds is antagonistic.
Statistical analysis
All computations were performed according to 
Tallarida (2000) and Tallarida and Murray (1986). At each 
time interval the differences between the corresponding 
means were verified using one‑way analysis of variance 
(ANOVA), followed by Tukey’s HSD post hoc test. Two 
regression lines were compared by the test for parallelism 
and the relative potency test (Tallarida and Murray 1986). 
The potency ratio was considered statistically significant 
when 95% of the confidence limits (CL) did not overlap 
1.0 (P<0.05). A P<0.05 was considered to be statistically 
significant.
RESULTS
The influence of magnesium sulfate on the 
formalin test in rats
Administered alone, magnesium sulfate (5 mg/kg 
and 30 mg/kg) did not produce any effect in comparison 
with control (0.9% NaCl) in the formalin test in rats 
(P>0.05) (Fig. 1). At dose of 15 mg/kg, magnesium 
sulfate had antinociceptive effects in the period during 
15–25 min after the formalin injection (P<0.05). The 
effect of magnesium sulfate was not dose‑dependent. 
For time intervals: 0–5, 5–10, 10–15, 15–20, 20–25, 
25–30, 30–35, 35–40, and 45–50 min, the F‑ and p‑values 
(ANOVA) were: [F3,20=2.964; p=0.057], [F3,20=2.024; 
p=0.143], [F3,20=1.286; p=0.306], [F3,20=4.926; p=0.010], 
[F3,20=5.128; p=0.009], [F3,20=1.437; p=0.262], [F3,20=1.135; 
p=0.359], [F3,20=1.129; p=0.361] and [F3,20=4.062; p=0.021], 
respectively.
The effect of ketamine in the formalin test in rats
When administered alone, ketamine (2, 2.5 and 
5 mg/kg) decreased the total time spent in pain‑related 
behavior after the injection of formalin (P<0.05) 
(Fig. 2). Ketamine inhibited the phase 2 responses in 
a dose‑dependent manner, but had a lower effect in 
phase 1. Statistical significance was observed between 
ketamine (2 and 2.5 mg/kg) and ketamine (5 mg/kg) 
in almost all 5‑min periods from 20 to 45 min. For time 
intervals: 0–5, 5–10, 10–15, 15–20, 20–25, 25–30, 30–35, 
35–40, and 45–50 min, the F‑ and p‑values (ANOVA) were: 
[F4,25=6.839; p=0.001], [F4,25=1.581; p=0.210], [F4,25=20.146; 
p=0.000], [F4,25=26.856; p=0.000], [F4,25=40.777; p=0.000], 
[F4,25=41.870; p=0.000], [F4,25=39.074; p=0.000], [F4,25=77.629; 
p=0.000] and [F4,25=124.574; p=0.000], respectively.
Fig. 2.The antinociceptive effect of ketamine in the formalin test in rats. Each point represents the mean ±SEM of the antinociceptive latency time in seconds 
(s) obtained in 6–8 rats. At each time interval the differences between the corresponding means were verified using one‑way analysis of variance (ANOVA; 
F‑value, p‑value), followed by Tukey’s HSD post hoc test where statistical significance was determined by comparing with the control (0.9% NaCl) (*P<0.05); 
with KT(2) (◊P<0.05); with KT (2.5) (¤P<0.05). 
5_882_Vujovic_v5.indd   140 23/06/17   19:09
Magnesium and ketamine in the formalin test 141Acta Neurobiol Exp 2017, 77: 137–146
The effects of the combinations of 
ketamine‑magnesium sulfate and magnesium 
sulfate‑ketamine in the formalin test in rats
Different doses of ketamine (2, 2.5 and 5 mg/kg) and 
magnesium sulfate (5 mg/kg) were combined and tested 
(Fig. 3A). Both combinations (ketamine‑magnesium sulfate 
administration and magnesium sulfate administration 
prior to ketamine administration) produced a significant 
effect compared to the control (0.9% NaCl) (P<0.05). 
The ketamine‑magnesium sulfate combination 
had a dose‑dependent effect (Fig. 3A). The effect of 
Fig. 3. The antinociceptive effect of the ketamine‑magnesium sulfate combination (A) and magnesium sulfate‑ketamine combination (B) in the formalin 
test in rats. Each point represents the mean ±SEM of the antinociceptive latency time in  seconds (s) obtained in 6–8 rats. At each time interval the 
differences between the corresponding means at each time interval were verified using one‑way analysis of variance (ANOVA; F‑value, p‑value), followed by 
Tukey’s HSD post hoc test where statistical significance was determined by comparing with the control (0.9% NaCl; *P<0.05); with KT(2)+MG(5)/MG(5)+KT(2) 
(◊P<0.05); with KT(2.5)+MG(5)/MG(5)+KT(2.5) (□P <0.05). 
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the ketamine (2 mg/kg)‑magnesium sulfate (5 mg/kg) 
combination was significantly higher compared to the 
control (0.9% NaCl) at time points of 5–25 min (P<0.05). 
The effect of the ketamine (2.5 and 5 mg/kg)‑magnesium 
sulfate (5 mg/kg) combination was significantly higher 
compared to the control (0.9% NaCl) at time points of 
10–45 min (P<0.05). For time intervals: 0–5, 5–10, 10–15, 
15–20, 20–25, 25–30, 30–35, 35–40, and 45–50 min, the 
F‑ and p‑values (ANOVA) were: [F4,25=19.597; p=0.000], 
[F4,25=28.838; p=0.000], [F4,25=19.950; p=0.000], [F4,25=21.083; 
p=0.000], [F4,25=89.298; p=0.000], [F4,25=204.658; p=0.000], 
[F4,25=504.817; p=0.000], [F4,25=216.012; p=0.000] and 
[F4,25=200.393; p=0.000], respectively.
The magnesium sulfate‑ketamine combination did not 
show a dose‑dependent effect (Fig. 3B). The administration 
of magnesium sulfate (5 mg/kg, sc) followed by ketamine 
(5 mg/kg, ip) administration after 5 min, produced 
a significant reduction in formalin‑induced pain at the 
time points from 15–45 min (P<0.05; Fig. 3B). However, 
magnesium sulfate (5 mg/kg) injected 5 min before the 2 and 
2.5 mg/kg doses of ketamine did not affect the nociception 
(P<0.05; Fig. 3B). For time intervals: 0–5, 5–10, 10–15, 15–20, 
20–25, 25–30, 30–35, 35–40, and 45–50 min, the F‑ and 
p‑values (ANOVA) were: [F3,20=11.184; p=0.001], [F3,20=5.129; 
p=0.009], [F3,20=17.438; p=0.000], [F3,20=95.033; p=0.000], 
[F3,20=96.769; p=0.000], [F3,20=125.415; p=0.000], [F3,20=88.641; 
p=0.000], [F3,20=39.157; p=0.000] and [F3,20=59.436; p=0.000], 
respectively.
Interactions between ketamine and magnesium 
sulfate
Additive interaction between ketamine and magnesium sulfate
The interaction between ketamine (the drug 
that exerted high antinociceptive efficacy and 
dose‑dependent effect in rats) and magnesium sulfate 
(the drug that exerted low antinociceptive efficacy in 
rats and a non‑dose‑dependent effect) was evaluated 
by co‑administration of a fixed, subeffective dose of 
magnesium sulfate along with increasing doses of 
ketamine (Gaitan and Herrero 2002). The antinociceptive 
effects of ketamine were assessed from the corresponding 
log dose‑response curve (ED50=2 mg/kg). In the next step, 
we examined the combination of a fixed quantity dose of 
magnesium sulfate (5 mg/kg) along and 3 different doses 
(2, 2.5 and 5 mg/kg, ip) of ketamine (fixed fractions of 
the ED50: 1 ED50, 5/4 ED50, 2 ED50). Lower doses of ketamine 
(1 mg/kg) in combination with magnesium sulfate 
(5 mg/kg) did not have a significant effect when compared 
with the control (not shown). The log dose‑response 
curves for ketamine (2, 2.5 and 5 mg/kg, ip) administered 
alone, and ketamine (2, 2.5 and 5 mg/kg, ip) administered 
prior to the administration of a fixed dose of magnesium 
sulfate (5 mg/kg, sc), were constructed and compared 
(Fig. 4A). There was a non‑significant leftward shift of 
the log dose‑response regression curve for ketamine in 
the presence of magnesium sulfate, compared with the 
Fig. 4. Log dose‑response for (A) ketamine (KT; 2, 2.5 and 5 mg/kg; sc) and the 
ketamine (2, 2.5 and 5 mg/kg)‑magnesium sulfate (5 mg/kg) combination; 
(B) ketamine (KT; 2, 2.5 and 5  mg/kg; sc) and the magnesium sulfate 
(5  mg/kg)‑ketamine (2, 2.5 and 5  mg/kg) combination; (C) the ketamine 
(2, 2.5 and 5 mg/kg)‑magnesium sulfate (5 mg/kg) and magnesium sulfate 
(5 mg/kg)‑ketamine (2, 2.5 and 5 mg/kg) combinations in the formalin test 
in rats. Data are expressed as a percent of antinociception − AA (%). 
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log dose‑response regression curve for ketamine alone 
(P>0.05; relative potency test). This points to an additive 
interaction between ketamine and magnesium sulfate. 
The potency ratio was 1.2 (CL 0.95–1.38). The slopes are 
not significantly different (P<0.05; test for parallelism).
Antagonistic interaction between ketamine and magnesium 
sulfate
We compared the curves obtained for ketamine 
alone and the magnesium sulfate‑ketamine combination 
(Fig. 4B), where ketamine was administered after the 
magnesium‑sulfate. There was a significant rightward 
shift of the log dose‑response regression curve for 
ketamine in the presence of magnesium sulfate, when 
compared with the log dose‑response regression curve 
for ketamine alone (P<0.05; relative potency test). This 
points to antagonism between ketamine and magnesium 
sulfate in the formalin test in rats. The potency ratio was 
1.6 (CL 1.2–2.4), confirming an antagonistic interaction. 
The slopes are not significantly different (P<0.05; test for 
parallelism).
The potency of a  ketamine/magnesium sulfate combination is 
influenced by the order of drug administration
Fig. 4C illustrates the log dose‑response curves 
for ketamine‑magnesium sulfate and magnesium 
sulfate‑ketamine combinations. There was a significant 
rightward shift of the log dose‑response regression 
curve for the magnesium sulfate‑ketamine combination 
compared to the log dose‑response regression curve for the 
ketamine‑magnesium sulfate combination, which indicates 
the importance of the order of drug administration. The 
slopes are not significantly different (P<0.05; test for 
parallelism). The potency ratio was 1.8 (CL 1.4–2.5).
DISCUSSION
The major findings in the present study are the 
additive and antagonistic interactions between two NMDA 
antagonists, ketamine and magnesium sulfate, in the 
second phase of the formalin test in rats. We combined 
ketamine, a drug with a high antinociceptive efficacy, and 
magnesium sulfate, drug with low antinociceptive efficacy. 
However, the administration of magnesium before or 
after ketamine resulted in an increase or decrease in 
the time the animals spent in pain‑related behavior, 
respectively. For the first time, it was demonstrated that 
in inflammatory pain the order of administration of these 
medications is important; a lower level of activity was 
demonstrated when magnesium sulfate was administered 
before ketamine. Also, this is the first study to show 
additive and antagonistic interactions between ketamine 
and magnesium sulfate with statistical confirmation.
In agreement with the findings of the present work, 
Ishizaki and others (1999) showed that intrathecal 
magnesium sulfate produced a depression of pain 
responses in the formalin test only after the first 10 min. 
The authors concluded that magnesium sulfate did not 
display remarkable antinociceptive effects in acute pain 
models. Similar to this, Takano and colleagues (2000) 
reported that the intrathecal injection of magnesium was 
capable of decreasing the second phase responses in the 
formalin test in a dose‑dependent manner. However, Begon 
and others (2002) showed that systemic administration 
of magnesium sulfate (30 and 90 mg/kg, ip) had no effect 
on the second phase of the formalin test. On the contrary, 
it was demonstrated that intraperitoneal magnesium 
oxide had an antinociceptive effect in both phases of 
the formalin test, as well as in the writhing test in mice 
(Jahangiri et al. 2013). Our previous results showed that 
magnesium sulfate and MK‑801 are effective against acetic 
acid‑induced visceral and carrageenan‑induced somatic 
inflammatory pain models in rats (Vuckovic et al. 2015a). 
Unlike MK‑801, the effects of magnesium sulfate were not 
dose‑dependent. In the present experiments magnesium 
sulfate demonstrated a low antinociceptive activity in the 
formalin test in rats.
In rodents, the systemic administration of ketamine 
suppressed pain‑related behavior (Sawynok and Reid 
2002, Bulutcu et al. 2002, Petrenko et al. 2006, do Vale 
et al. 2016) and paw swelling (Sawynok and Reid 2002, 
do Vale et al. 2016) induced by formalin injection into 
the paw. Ketamine (5–10 mg) reduced the pain response 
in the second phase (Bulutcu et al. 2002, Petrenko 
et al. 2006) or in both phases (do Vale et al. 2016) of 
the formalin test. Also, ketamine at as low a dose as 
0.1 mg/kg decreased the time of licking of the inflamed 
paw in both phases of the formalin test in mice, and 
co‑administration of conventional/nanoparticle 
magnesium oxide potentiated the effect of ketamine 
(Jahangiri et al. 2013). In the present experiments 
magnesium sulfate demonstrated a more pronounced 
antinociceptive activity in the second phase of the 
formalin test. 
Analysis of the log dose‑response curves for the 
effects of ketamine and the magnesium sulfate‑ketamine 
combination in formalin‑induced nociception revealed 
an antagonistic interaction and a 1.6 (CL 1.2–2.4)‑fold 
increment in ketamine dosage when ketamine was 
applied after the magnesium sulfate. In addition, a low 
dose of magnesium sulfate (5 mg/kg, sc) administered 
after ketamine, increased the antinociceptive effect of 
ketamine by a factor of only 1.2 (CL 0.95–1.38), pointing 
to an additive interaction. Therefore, the order of 
administration of these drugs is most likely important. 
5_882_Vujovic_v5.indd   143 23/06/17   19:09
144 K. Savić Vujović et al. Acta Neurobiol Exp 2017, 77: 137–146
There was a 1.8‑fold reduction in the ketamine effect 
when ketamine was administered before rather than 
after magnesium sulfate. We have previously reported 
that the efficacy of the ketamine‑magnesium sulfate 
combination in the acute pain (tail immersion) test 
in rats is influenced by the order of medication 
administration (Savic Vujovic et al. 2015, Vučković et 
al. 2015b); a higher level of activity was demonstrated 
when ketamine was administered before magnesium 
sulfate (Savic Vujovic et al. 2015, Vučković et al. 2015b). 
The results of the present study are in agreement with 
previous ones.
The mechanism that underlies the magnesium and 
ketamine interaction at the level of the NMDA receptor 
is not clear. We previously hypothesized that when 
applied first, the magnesium ions block the NMDA ion 
channel before ketamine binds to the phencyclidine site, 
thus reducing its antinociceptive action (Savic Vujovic 
et al. 2015). Since a synergistic interaction between 
ketamine and magnesium was previously observed 
in acute nociceptive pain in rats (Savic Vujovic et al. 
2015), we also hypothesized that the type of interaction 
between ketamine and magnesium depends on the pain 
model. Acute nociceptive and inflammatory pain are 
characterized by low and high levels of NMDA receptor 
activity, respectively (Voscopoulos and Lema 2010). In 
a previous study we showed that ketamine and magnesium, 
both NMDA antagonists, are not effective against acute 
pain when administered alone (Savic Vujovic et al. 2015). 
However, in this study of inflammatory pain, they are 
more and less effective, respectively. Ketamine decreases 
the “wind up” phenomenon, and the antagonism is more 
important if the NMDA channel has been previously 
opened by glutamate binding (“use dependence”) 
(Mion and Villevieille 2013, Ziv et al. 2016). This “use 
dependence” concept can explain why ketamine is more 
efficient in intense or chronic pain (De Kock et al. 2001) 
and less efficient in acute pain (Savic Vujovic et al. 2015), 
or when NMDA receptor activity is lowered by magnesium, 
as is the case herein.
Further possible explanations for the diverse 
interactions between ketamine and magnesium may 
be due to the allosteric modulation of NMDA receptors. 
The N‑terminal domains (NTDs) of GluN2B receptors 
contain a modulatory site that allows positive allosteric 
modulation (Mony et al. 2009). This site binds spermine 
and spermidine, endogenous polyamines, as well as 
the magnesium ion. A general mechanistic model for 
allosteric signaling, both positive and negative via the 
NTDs, has been proposed (Lu et al. 1998, Mony et al. 2009, 
Zhu et al. 2015).
The interaction between ketamine and magnesium 
described in this study might be due to some other 
mechanisms that do not involve NMDA receptors. 
Ketamine increases the release of monoamine 
neurotransmitters (norepinephrine, dopamine and 
serotonin) and inhibits their uptake, thus enhancing the 
descending inhibitory pain pathways (Tso et al. 2004, 
Koizuka et al. 2005). Ketamine can also interact with 
nicotinic cholinergic (Scheller et al. 1996, Yamakura 
et al. 2000), monoaminergic (Kapur and Seeman 2002) 
and opioid (Sarton et al. 2001, Pacheco Dda et al. 2014) 
receptors and nitric oxide synthase (do Vale et al. 2016), as 
well as with hyperpolarisation‑activated cyclic nucleotide 
channels (HCN1) (Chen et al. 2009).
Magnesium also blocks presynaptic and postsynaptic 
calcium channels, modulates potassium channels and 
functions through other mechanisms of action (Matsuda 
et al. 1987, Bara et al. 1993, Mak and Foskett 1998, Shi and 
Cui 2001, Shi et al. 2002, Shimosawa et al. 2004, Guiet‑Bara 
et al. 2007). In studies using inhibitors of NOS it was 
recently suggested that the activation of the NO pathway 
could have an important role in the antinociceptive 
effects of systemic magnesium sulfate in rats with 
inflammatory pain (Srebro et al. 2014). It has also been 
reported that magnesium deficiency produces mechanical 
hyperalgesia in rats which can be reversed by NMDA 
receptor antagonists (Dubray et al. 1997, Begon et al. 
2001, 2002). Magnesium deficiency induces sensitization 
of nociceptive pathways which involves NMDA receptors. 
Oral administration of magnesium can restore thermal 
hyperalgesia and magnesium deficiency in diabetic rats 
(Hasanein et al. 2006).
Literature data indicate that both ketamine and 
magnesium increase opioid antinociception in different 
animal models of pain (Begon et al. 2002, Alvarez et al. 
2003, Savic Vujovic et al. 2015, Bujalska‑Zadrożny et 
al. 2016). In addition, evidence for the involvement 
of endogenous opioids and mu and delta opioid 
receptors in ketamine‑induced antinociception has 
been presented (Sarton et al. 2001, Pacheco Dda et 
al. 2014). Our previous study demonstrated that the 
morphine‑ketamine‑magnesium sulfate combination 
was antagonized by naloxone, an antagonist of opioid 
receptors, indicating that this interaction is most likely 
mediated via opioid receptors (Vučković et al. 2015b). 
The NMDA receptor has been shown to associate 
post‑synaptically with mu receptor (Rodrigez‑Munoz 
et al. 2012). When morphine activates the mu receptor, 
the resulting phosphorylation of a residue of the NMDA 
receptor causes the dissociation of both receptors and mu 
receptor desensitization (Rodrigez‑Munoz et al. 2012). 
Like ketamine, magnesium is a NMDA receptor antagonist 
and can prevent NMDA receptor phosphorylation and 
opioid‑induced hyperalgesia (Bujalska‑Zadrożny et al. 
2016).
In the second phase of the rat formalin test we 
observed both additive and antagonistic interactions 
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between ketamine and magnesium sulfate. The type 
of interaction depends on the order of administration 
of these drugs. Similar to our previous results obtained 
on the model of acute nociceptive pain in rats, higher 
antinociceptive activity was observed when ketamine was 
administered before magnesium. The present study also 
revealed an antagonistic interaction when magnesium 
sulfate was administered before ketamine. Studies in 
which a ketamine‑magnesium combination was examined 
in humans provided conflicting results. A double‑blind 
randomized controlled trial group of patients treated 
during induction of general anesthesia with a combination 
of magnesium sulfate and S(+)‑ketamine showed a trend 
towards more opioid piritramide use postoperatively 
via patient controlled analgesia (PCA) device compared 
with ketamine alone (Stessel at al. 2013), suggesting an 
antagonistic effect of magnesium on ketamine analgesia. 
In contrast to this, the combined use of ketamine and 
magnesium reduced morphine consumption after scoliosis 
surgery in a prospective randomised double‑blind study 
(Jabbour et al. 2014). However, the order of administration 
of these drugs in human studies has not been reported.
Since pain often has a mixed etiology, with nociceptive, 
inflammatory and neuropathic components, it is always 
advisable to administer ketamine before magnesium 
in situations when the two drugs are applied together. 
Further studies are needed to confirm the clinical 
relevance of the order of ketamine and magnesium 
sulfate administration in different types of pain (i.e. 
postoperative, cancer).
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